FIELD: medicine.
SUBSTANCE: group of inventions relates to medicine. Described are bioactive agents, introduced by means of oral rapidly dispersible/dissolving systems, releasing medications for the treatment of diseases in patients with critical pathological states of the oral cavity, resulting in difficulties in swallowing oral drug forms and, sequentially, to difficulties in the treatment of dysphagia, and/or odynophagia, and/or aspiration risk.
EFFECT: orally dosed forms rapidly disintegrate in the oral cavity in interaction with saliva and do not require addition of water to accelerate disintegration.
18 cl, 1 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ORALLY DECOMPOSING POWDER, CONTAINING CILOSTAZOL AND MANNITOL | 2006 |
|
RU2426529C2 |
| CRYOGENICALLY DRIED ONDASTERON COMPOSITIONS AND METHOD FOR TREATING MAMMALS | 1995 |
|
RU2159614C2 |
| ANTIEMETIC EXTENDED RELEASE SOLID DOSAGE FORMS | 2014 |
|
RU2679448C2 |
| ORALLY DISINTEGRATING TABLET TEMAZEPAM COMPOSITIONS | 2008 |
|
RU2524638C2 |
| SYSTEMS OF DELIVERING MEDICAL SUBSTANCES, INCLUDING WEAKLY BASIC MEDICINAL SUBSTANCES AND ORGANIC ACIDS | 2009 |
|
RU2504362C2 |
| COMPOSITE COMPOUND OF PARACETAMOL FOR ORAL USE | 2019 |
|
RU2755087C1 |
| COMPOSITION OF FAST DISINTEGRATING SOLID DOSAGE FORM, INCLUDING FUNCTIONALIZED CALCIUM CARBONATE AND METHOD FOR ITS PREPARATION | 2013 |
|
RU2676087C2 |
| METHODS FOR TREATMENT OF EOSINOPHILIC ESOPHAGITIS | 2017 |
|
RU2766577C2 |
| PHARMACEUTICAL IBANDRONATE-CONTAINING PREPARATION FOR ORAL USAGE | 1997 |
|
RU2193881C2 |
| TRANSDERMAL GRANISETRON | 2004 |
|
RU2355387C2 |
